Grail Inc
NASDAQ:GRAL
Grail Inc
NASDAQ:GRAL
Price:
100.29
USD
0.22%
Market Closed
Market Cap:
$3.9B
Relative Value
The Relative Value of one
GRAL
stock under the Base Case scenario is
20.73
USD.
Compared to the current market price of 100.29 USD,
Grail Inc
is
Overvalued by 79%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
GRAL
Relative Value
Base Case
20.73
USD
Overvaluation 79%
Multiples Across Competitors
GRAL Competitors Multiples
Grail Inc Competitors
Grail Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Grail Inc
NASDAQ:GRAL
|
3.6B USD | 25.6 | -8.9 | -7.9 | -5.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
394.1B USD | 6.6 | 167.9 | 16.3 | 23.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.3B USD | 5.5 | 26.4 | 15.1 | 15.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.3B USD | 6.5 | 23.2 | 15.8 | 15.8 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.5B USD | 10.2 | 32.5 | 23.9 | 24.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
81.8B USD | 5.7 | 18.1 | 15.4 | 17.6 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.4B AUD | 3.9 | 20.4 | 13.6 | 17 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42.4B EUR | 14.1 | 33 | 56.3 | 57.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
